welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials


Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.

“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”

Novo Biosciences Achieves Major Milestones In Moving Trodusquemine Into Clinical Trials